Protagenic Therapeutics, Inc. (PTIXW) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in New York City, NY, United States. The current CEO is Garo H. Armen.
PTIXW has IPO date of 2021-04-27, 1 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $27.16K.
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
